



# 華控康泰集團有限公司

**Kontafarma China Holdings Limited**

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code: 1312)

23 June 2023

Listing Division  
The Stock Exchange of Hong Kong Limited  
12/F, Two Exchange Square  
8 Connaught Place Central  
Hong Kong

Dear Sirs/Madams,

**Re: Circular — Major Transaction in relation to Disposal of an Indirect Non-Wholly Owned Subsidiary**

We, Kontafarma China Holdings Limited (the “**Company**”) (stock code: 1312), refer to the circular of the Company dated 23 June 2023 (the “**Circular**”) of which this letter forms part. Unless the context otherwise requires, terms defined in the Circular shall have the same meanings when used herein.

We refer to the Valuation conducted by Beijing Zhongtianhua Asset Appraisal Co., Ltd.\* (北京中天華資產評估有限責任公司) (the “**Valuer**”), an independent valuer. The Valuation adopted, among other things, an income approach which is based on the discounted future estimated cash flows and is regarded as a profit forecast (the “**Profit Forecast**”) under Rule 14.61 of the Listing Rules. We have discussed with the Valuer the different aspects upon which the Valuation was prepared (including the principal and commercial assumptions) and have reviewed the Valuation for which the Valuer is responsible.

Pursuant to Rule 14.62 of the Listing Rules, we have also engaged BDO Limited, acting as the Company’s reporting accountants, to report on the arithmetical accuracy of the calculations of the discounted future estimated cash flows (which does not involve the adoption of accounting policies), and considered the report from BDO Limited which was prepared in accordance with the Hong Kong Standard on Assurance Engagements 3000 (Revised) “Assurance Engagements Other Than Audits or Reviews of Historical Financial Information” issued by the Hong Kong Institute of Certified Public Accountants, as set out in Appendix IV to the Circular.

On the basis of the above, we confirm that the Profit Forecast used in the Valuation has been made after due and careful enquiry by us.

Yours faithfully,  
On behalf of the Board

**Kontafarma China Holdings Limited**  
**Bai Pingyan**  
Chairman

\* For identification purposes only